TY - JOUR
AU - Onji, Morikazu
AB - Abstract Objective Transcatheter arterial embolization (TAE) with gelatin sponge particles and iodized oil often yields poor results when used to treat unresectable multifocal hepatocellular carcinoma (HCC). The present study retrospectively investigated the utility of a novel combination chemotherapy regimen for treating multifocal HCC resistant to TAE. Methods Thirteen consecutive patients with unresectable multifocal HCC and resistance to TAE were treated with combination chemotherapy consisting of arterial chemoembolization with degradable starch microspheres (DSM) (150–4500 mg on Day 1), mitomycin-C (4–8 mg on Day 1), continuous arterial infusion of 5-fluorouracil (1250 mg/120 h), cisplatin (25–50 mg/120 h) and l-leucovorin (125 mg/120 h) for 10–19 weeks. Results The response rate was 84.6%, with complete response in one patient and partial response (PR) in 10 patients. In four of 10 patients with PR, the tumor was not observable, although the tumor marker did not completely decline to the normal range. The 1-, 2- and 3-year survival rates were 100, 28.9 and 9.6% in all, and 100, 33.3 and 0% in six patients with portal vein tumor thrombosis (PVTT). The median survival was 22.1 months in all and 17.1 months in six patients with PVTT. Thrombocytopenia of Grade III or higher was observed in eight patients. Laparoscopic splenectomy was performed before therapy in four patients with platelet counts of <70 000/mm3, and during therapy in five patients with severe thrombocytopenia. Conclusions This novel chemotherapy regimen achieved favorable results and may be useful in treating patients with unresectable multifocal HCC resistant to TAE. hepatocellular carcinoma, degradable starch microspheres, transcatheter arterial embolization, hepatic arterial infusion INTRODUCTION Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, and recent advances in ultrasonography (US), computed tomography (CT), digital subtraction angiography (DSA) and magnetic resonance imaging (MRI) have enabled its early detection. Furthermore, several non-surgical modalities have been developed for the treatment of unresectable HCC, including percutaneous ethanol injection (PEI) (1), microwave coagulation therapy (MCT) (2) and radiofrequency ablation (RFA) (3). As a result, the prognosis for patients with HCC has improved considerably (4). However, there are a considerable number of patients with advanced multifocal HCC at first diagnosis that cannot be treated with these new modalities (4). Moreover, multicentric carcinogenesis and intrahepatic metastases make the recurrence rate for HCC high (5). Since almost all patients with HCC eventually develop multifocal tumors, development of a standard therapy for patients with advanced multifocal HCC would be beneficial. Owing to the extensive vascularity of most hepatic tumors, transcatheter arterial embolization (TAE) with gelatin sponge particles and iodized oil is a useful alternative for the treatment of advanced multifocal HCC (6). In particular, TAE is useful for nodular type HCCs that possess capsules, and that are supplied by the hepatic artery (7,8) but is not as useful for the following tumors with portal vein flow (8): (i) non-nodular type tumors without capsules, such as massive or diffuse growth types (7,9); (ii) nodular type tumors with incomplete capsules, such as contiguous multinodular (CMN) growth type and single nodule with extranodular (SNE) growth type (7); (iii) tumors with thrombosis in hepatic vessels (9) and (iv) small intrahepatic metastases without capsules (8). HCC has low-grade sensitivity to several anti-cancer drugs (10–14). Thus, advanced HCC selected for chemotherapy has a dismal prognosis, with a median survival duration of <6 months (11–16). Recent developments in implantable drug delivery systems have enabled the repetition of arterial infusion of chemotherapeutic agents for advanced HCC (17–22), and the efficacies of several chemotherapeutic regimens using arterial infusion of 5-fluorouracil (5-FU) with its biochemical modulators, such as cisplatin (CDDP) (17–21), leucovorin (LV) (20–22) and interferon-alpha (IFN-alpha), (20,22) have been reported. Mitomycin-C (MMC) is a dose-dependent agent with powerful and broad-spectrum anti-cancer effects (23). Use of MMC with degradable starch microspheres (DSM) can increase the anti-cancer effects while reducing the side effects. DSM, which is made from potato starch and produces transient occlusion of small arteries (24,25), has been used with anti-cancer agents for the treatment of metastatic liver cancer and HCC (25–28). However, combination treatment using chemoembolization with DSM and continuous arterial infusion of 5-FU has not been reported. We previously experienced excellent results in three patients with metastatic liver tumors from primary colorectal cancer, who were treated with a combination of arterial chemoembolization with DSM and MMC and arterial infusion chemotherapy using 5-FU and l-LV [Isovorin, (l-LV)]. Thus, the goal of the present retrospective study was to determine the therapeutic utility of novel chemotherapy using arterial chemoembolization with DSM and MMC, and continuous arterial infusion 5-FU with its biochemical modulators for the patients with TAE-resistant HCC. PATIENTS AND METHODS Patients Between April 2002 and December 2003, 102 Japanese patients with unresectable multifocal HCC were admitted to the Department of Internal Medicine III of Ehime University Hospital. Thirteen consecutive patients were regarded as having TAE-resistant HCC according to the criteria outlined here, and were enrolled in this study. They included six patients with portal vein tumor thrombosis (PVTT). A diagnosis of HCC was made by histological findings, imaging studies, elevated serum alpha-fetoprotein (AFP) and/or des-gamma-carboxyprothrombin (DCP) levels. All patients were deemed poor candidates for surgical resection or non-surgical treatment modalities, including PEI, MCT and RFA, because of HCC progression or poor liver function. Characteristics of patients and tumors are shown in Tables 1 and 2, respectively. Table 1. Characteristics of patients with HCC, treated with a new chemotherapeutic regimen Case no. . Age (years) . Gender . Hepatitis . Platelet (×105/mm3) . T.Bil (mg/dl) . Albumin (g/dl) . PT (%) . ICGR15 (%) . Child-Pugh classification (score) . 1 61 M HCV 8.5 0.5 4.5 79.2 6.4 A (6) 2 58 M HCV 11.9 0.5 3.7 81.1 24.0 A (5) 3 67 M HCV 10.0 0.5 3.4 84.0 12.9 A (6) 4 54 M HCV 10.2 2.1 3.0 55.7 53.6 B (9) 5 70 M HCV 17.9 0.7 3.3 94.9 41.0 A (6) 6 52 M Cryptogenic 7.2 0.7 3.4 88.6 26.6 A (6) 7 58 M HCV 8.01 (5.2)2 1.4 3.1 66.0 60.0 B (7) 8 70 M HCV 18.6 0.6 4.1 118.2 12.0 A (5) 9 53 M HCV 16.71 (3.5)2 0.9 2.8 93.7 41.0 B (9) 10 68 M HCV 13.8 0.5 3.2 102.2 16.0 A (6) 11 50 M HCV 9.8 2.1 3.7 89.5 48.0 B (7) 12 67 M HCV 19.01 (6.7)2 0.9 2.7 104.7 45.9 B (7) 13 56 M HCV 15.91 (6.9)2 0.7 3.5 73.8 22.0 B (7) Case no. . Age (years) . Gender . Hepatitis . Platelet (×105/mm3) . T.Bil (mg/dl) . Albumin (g/dl) . PT (%) . ICGR15 (%) . Child-Pugh classification (score) . 1 61 M HCV 8.5 0.5 4.5 79.2 6.4 A (6) 2 58 M HCV 11.9 0.5 3.7 81.1 24.0 A (5) 3 67 M HCV 10.0 0.5 3.4 84.0 12.9 A (6) 4 54 M HCV 10.2 2.1 3.0 55.7 53.6 B (9) 5 70 M HCV 17.9 0.7 3.3 94.9 41.0 A (6) 6 52 M Cryptogenic 7.2 0.7 3.4 88.6 26.6 A (6) 7 58 M HCV 8.01 (5.2)2 1.4 3.1 66.0 60.0 B (7) 8 70 M HCV 18.6 0.6 4.1 118.2 12.0 A (5) 9 53 M HCV 16.71 (3.5)2 0.9 2.8 93.7 41.0 B (9) 10 68 M HCV 13.8 0.5 3.2 102.2 16.0 A (6) 11 50 M HCV 9.8 2.1 3.7 89.5 48.0 B (7) 12 67 M HCV 19.01 (6.7)2 0.9 2.7 104.7 45.9 B (7) 13 56 M HCV 15.91 (6.9)2 0.7 3.5 73.8 22.0 B (7) HCC, hepatocellular carcinoma; T.Bil, total bilirubin; PT, prothrombin time; ICGR15, indocianogreen test at 15 min; M, male; HCV, hepatitis C virus. 1Number of platelets after splenectomy. 2Number of platelets before splenectomy. Open in new tab Table 1. Characteristics of patients with HCC, treated with a new chemotherapeutic regimen Case no. . Age (years) . Gender . Hepatitis . Platelet (×105/mm3) . T.Bil (mg/dl) . Albumin (g/dl) . PT (%) . ICGR15 (%) . Child-Pugh classification (score) . 1 61 M HCV 8.5 0.5 4.5 79.2 6.4 A (6) 2 58 M HCV 11.9 0.5 3.7 81.1 24.0 A (5) 3 67 M HCV 10.0 0.5 3.4 84.0 12.9 A (6) 4 54 M HCV 10.2 2.1 3.0 55.7 53.6 B (9) 5 70 M HCV 17.9 0.7 3.3 94.9 41.0 A (6) 6 52 M Cryptogenic 7.2 0.7 3.4 88.6 26.6 A (6) 7 58 M HCV 8.01 (5.2)2 1.4 3.1 66.0 60.0 B (7) 8 70 M HCV 18.6 0.6 4.1 118.2 12.0 A (5) 9 53 M HCV 16.71 (3.5)2 0.9 2.8 93.7 41.0 B (9) 10 68 M HCV 13.8 0.5 3.2 102.2 16.0 A (6) 11 50 M HCV 9.8 2.1 3.7 89.5 48.0 B (7) 12 67 M HCV 19.01 (6.7)2 0.9 2.7 104.7 45.9 B (7) 13 56 M HCV 15.91 (6.9)2 0.7 3.5 73.8 22.0 B (7) Case no. . Age (years) . Gender . Hepatitis . Platelet (×105/mm3) . T.Bil (mg/dl) . Albumin (g/dl) . PT (%) . ICGR15 (%) . Child-Pugh classification (score) . 1 61 M HCV 8.5 0.5 4.5 79.2 6.4 A (6) 2 58 M HCV 11.9 0.5 3.7 81.1 24.0 A (5) 3 67 M HCV 10.0 0.5 3.4 84.0 12.9 A (6) 4 54 M HCV 10.2 2.1 3.0 55.7 53.6 B (9) 5 70 M HCV 17.9 0.7 3.3 94.9 41.0 A (6) 6 52 M Cryptogenic 7.2 0.7 3.4 88.6 26.6 A (6) 7 58 M HCV 8.01 (5.2)2 1.4 3.1 66.0 60.0 B (7) 8 70 M HCV 18.6 0.6 4.1 118.2 12.0 A (5) 9 53 M HCV 16.71 (3.5)2 0.9 2.8 93.7 41.0 B (9) 10 68 M HCV 13.8 0.5 3.2 102.2 16.0 A (6) 11 50 M HCV 9.8 2.1 3.7 89.5 48.0 B (7) 12 67 M HCV 19.01 (6.7)2 0.9 2.7 104.7 45.9 B (7) 13 56 M HCV 15.91 (6.9)2 0.7 3.5 73.8 22.0 B (7) HCC, hepatocellular carcinoma; T.Bil, total bilirubin; PT, prothrombin time; ICGR15, indocianogreen test at 15 min; M, male; HCV, hepatitis C virus. 1Number of platelets after splenectomy. 2Number of platelets before splenectomy. Open in new tab Table 2. Tumor characteristics and clinical outcome of patients with HCC, treated with a new chemotherapeutic regimen using TACE with DSM Case no. . Macroscopic classification1 . Tumor diameter2 (cm) . Location of tumor . Tumor thrombus1 . Treatment (weeks) . AFP (ng/ml) . DCP (mAU/ml) . Response3 . Outcome (months) . . . . . . . After . After . Before . After . . . 1 MN 3.0 Bilateral Vp2 12 28.3 22.2 26 27 PR 20.3, dead 2 MN 2.5 Bilateral — 11 361 22.3 65 22 PR 20.4, dead 3 CMN 6.0 Bilateral — 19 15 799 11.5 9330 19 CR 42.5, alive 4 MN 6.0 Bilateral Vp4 16 11.4 6.8 5190 131 PR 17.1, dead 5 Diffuse Whole right lobe Bilateral — 10 34.9 27.7 1490 55 PR 22.1, dead 6 Massive 7.0 Unilateral — 11 6850 952 6930 2210 PD 15.0, dead 7 MN 6.5 Bilateral Vp2 10 6204 97.6 10 6 PR 27.0, dead 8 MN 4.0 Bilateral — 10 391 26.9 219 11 PR 23.9, dead 9 MN 3.5 Bilateral — 10 5728 15.2 110 36 PR 29.6, dead 10 Massive 11.0 Bilateral Vp1 10 2.4 2.6 12 510 70 PR 13.8, dead 11 Diffuse Whole right lobe Bilateral Vp4 12 156 390 5104 11 727 37 PR 13.7, dead 12 MN 3.0 Bilateral — 13 424 220 322 234 PD 13.8, dead 13 MN 5.0 Bilateral Vp4 13 5358 908 45 26 PR 23.8, alive Case no. . Macroscopic classification1 . Tumor diameter2 (cm) . Location of tumor . Tumor thrombus1 . Treatment (weeks) . AFP (ng/ml) . DCP (mAU/ml) . Response3 . Outcome (months) . . . . . . . After . After . Before . After . . . 1 MN 3.0 Bilateral Vp2 12 28.3 22.2 26 27 PR 20.3, dead 2 MN 2.5 Bilateral — 11 361 22.3 65 22 PR 20.4, dead 3 CMN 6.0 Bilateral — 19 15 799 11.5 9330 19 CR 42.5, alive 4 MN 6.0 Bilateral Vp4 16 11.4 6.8 5190 131 PR 17.1, dead 5 Diffuse Whole right lobe Bilateral — 10 34.9 27.7 1490 55 PR 22.1, dead 6 Massive 7.0 Unilateral — 11 6850 952 6930 2210 PD 15.0, dead 7 MN 6.5 Bilateral Vp2 10 6204 97.6 10 6 PR 27.0, dead 8 MN 4.0 Bilateral — 10 391 26.9 219 11 PR 23.9, dead 9 MN 3.5 Bilateral — 10 5728 15.2 110 36 PR 29.6, dead 10 Massive 11.0 Bilateral Vp1 10 2.4 2.6 12 510 70 PR 13.8, dead 11 Diffuse Whole right lobe Bilateral Vp4 12 156 390 5104 11 727 37 PR 13.7, dead 12 MN 3.0 Bilateral — 13 424 220 322 234 PD 13.8, dead 13 MN 5.0 Bilateral Vp4 13 5358 908 45 26 PR 23.8, alive TACE, transcatheter arterial chemoembolization; DSM, degradable starch microspheres; AFP, alpha-fetoprotein; DCP, des-gamma-carboxyprothrombin; MN, multiple nodule type; CMN, contiguous multinodular type; Vp1, tumor thrombus in the third branch of portal vein; Vp2, tumor thrombus in the second branch of portal vein; Vp3, tumor thrombus in the first branch of portal vein; Vp4, tumor thrombus in trunk of portal vein. 1According to the Liver Cancer Study Group of Japan; 2Diameter of maximum tumor; 3According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Open in new tab Table 2. Tumor characteristics and clinical outcome of patients with HCC, treated with a new chemotherapeutic regimen using TACE with DSM Case no. . Macroscopic classification1 . Tumor diameter2 (cm) . Location of tumor . Tumor thrombus1 . Treatment (weeks) . AFP (ng/ml) . DCP (mAU/ml) . Response3 . Outcome (months) . . . . . . . After . After . Before . After . . . 1 MN 3.0 Bilateral Vp2 12 28.3 22.2 26 27 PR 20.3, dead 2 MN 2.5 Bilateral — 11 361 22.3 65 22 PR 20.4, dead 3 CMN 6.0 Bilateral — 19 15 799 11.5 9330 19 CR 42.5, alive 4 MN 6.0 Bilateral Vp4 16 11.4 6.8 5190 131 PR 17.1, dead 5 Diffuse Whole right lobe Bilateral — 10 34.9 27.7 1490 55 PR 22.1, dead 6 Massive 7.0 Unilateral — 11 6850 952 6930 2210 PD 15.0, dead 7 MN 6.5 Bilateral Vp2 10 6204 97.6 10 6 PR 27.0, dead 8 MN 4.0 Bilateral — 10 391 26.9 219 11 PR 23.9, dead 9 MN 3.5 Bilateral — 10 5728 15.2 110 36 PR 29.6, dead 10 Massive 11.0 Bilateral Vp1 10 2.4 2.6 12 510 70 PR 13.8, dead 11 Diffuse Whole right lobe Bilateral Vp4 12 156 390 5104 11 727 37 PR 13.7, dead 12 MN 3.0 Bilateral — 13 424 220 322 234 PD 13.8, dead 13 MN 5.0 Bilateral Vp4 13 5358 908 45 26 PR 23.8, alive Case no. . Macroscopic classification1 . Tumor diameter2 (cm) . Location of tumor . Tumor thrombus1 . Treatment (weeks) . AFP (ng/ml) . DCP (mAU/ml) . Response3 . Outcome (months) . . . . . . . After . After . Before . After . . . 1 MN 3.0 Bilateral Vp2 12 28.3 22.2 26 27 PR 20.3, dead 2 MN 2.5 Bilateral — 11 361 22.3 65 22 PR 20.4, dead 3 CMN 6.0 Bilateral — 19 15 799 11.5 9330 19 CR 42.5, alive 4 MN 6.0 Bilateral Vp4 16 11.4 6.8 5190 131 PR 17.1, dead 5 Diffuse Whole right lobe Bilateral — 10 34.9 27.7 1490 55 PR 22.1, dead 6 Massive 7.0 Unilateral — 11 6850 952 6930 2210 PD 15.0, dead 7 MN 6.5 Bilateral Vp2 10 6204 97.6 10 6 PR 27.0, dead 8 MN 4.0 Bilateral — 10 391 26.9 219 11 PR 23.9, dead 9 MN 3.5 Bilateral — 10 5728 15.2 110 36 PR 29.6, dead 10 Massive 11.0 Bilateral Vp1 10 2.4 2.6 12 510 70 PR 13.8, dead 11 Diffuse Whole right lobe Bilateral Vp4 12 156 390 5104 11 727 37 PR 13.7, dead 12 MN 3.0 Bilateral — 13 424 220 322 234 PD 13.8, dead 13 MN 5.0 Bilateral Vp4 13 5358 908 45 26 PR 23.8, alive TACE, transcatheter arterial chemoembolization; DSM, degradable starch microspheres; AFP, alpha-fetoprotein; DCP, des-gamma-carboxyprothrombin; MN, multiple nodule type; CMN, contiguous multinodular type; Vp1, tumor thrombus in the third branch of portal vein; Vp2, tumor thrombus in the second branch of portal vein; Vp3, tumor thrombus in the first branch of portal vein; Vp4, tumor thrombus in trunk of portal vein. 1According to the Liver Cancer Study Group of Japan; 2Diameter of maximum tumor; 3According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Open in new tab TAE-resistant HCC was defined by the following criteria: (i) tumors with enlargement of >20% in the sum of the longest diameter of the liver tumors on CT performed 2 months after TAE and (ii) tumors with thrombi in the hepatic vessels (9). Enrollment criteria included (i) age < 70 years; (ii) Child-Pugh classification > 9 points; (iii) absence of extrahepatic metastases; (iv) platelet count > 70 000/mm3; (v) creatinine clearance > 60 ml/h; (vi) successful implantation of intra-arterial catheter and drug delivery system; (vii) absence of the other life-threatening disease, with the exception of chronic liver disease; (viii) performance status [Eastern Cooperative Oncology Group (ECOG)] level 0–2 (29); and (ix). This retrospective study was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent. Ten patients had received TAE prior to enrollment in this study, and were diagnosed with TAE-resistant HCC by CT imaging 2 months after TAE (Criterion 1). The remaining three patients could not undergo TAE secondary to the presence of tumor thrombosis in the portal vein trunk (Criterion 2). The demographics of these patients are summarized in Table 1. Four patients with platelet counts of <70 000/mm3 before chemotherapy underwent laparoscopic splenectomy before entry into the study. Two patients had ascites of Grade 3 before the treatment. Catheter Implantation Celiac angiography was performed according to the femoral approach under local anesthesia. After the detection of HCC and its feeding arteries, a 5-Fr heparin-coated catheter was introduced into the proper or common hepatic artery. The gastroduodenal artery and the right gastric artery were occluded with metallic coils to prevent gastroduodenal injury by the anti-cancer drugs. Aberrant hepatic arteries, if present, were occluded with a metallic coil or a mixture (1:1.5) of n-butyl cyanoacrylate and iodized oil prior to the treatment for hepatic arterial redistribution (30). After the catheter was connected to the injection port, the device was implanted in a subcutaneous pocket in the femoral site. No patients received anticoagulant therapy. The device was filled with 5000 IU of a heparin solution to prevent occlusion. Before treatment, vascularity of tumors and enhanced area by contrast medium, were confirmed using CT angiography through an implanted reservoir catheter in all patients. Treatment Regimen As shown in Fig. 1, one course of chemotherapy consisted of a chemoembolization with a mixture of DSM (Spherex®; Yakult Co., Tokyo, Japan) and MMC (Mitomycin-S®; Kyowa Hakko Co., Tokyo, Japan), and twice 120-h continuous arterial infusions of 5-FU (Kyowa®; Kyowa Hakko Co), CDDP (Randa®; Nipponkayaku Co., Tokyo, Japan), and l-LV [Isovorin® (l-LV); Wyeth Co., Tokyo, Japan] over 2 weeks. Figure 1. Open in new tabDownload slide One course of chemotherapy consisted of a chemoembolizations with DSM and twice 120-h continuous arterial infusions of 5-fluorouracil (5-FU), l-leucovorin (l-LV) and cisplatin over 2 weeks. DSM, degradable starch microspheres; MMC, mitomycin-C. Figure 1. Open in new tabDownload slide One course of chemotherapy consisted of a chemoembolizations with DSM and twice 120-h continuous arterial infusions of 5-fluorouracil (5-FU), l-leucovorin (l-LV) and cisplatin over 2 weeks. DSM, degradable starch microspheres; MMC, mitomycin-C. First, a mixture of DSM (150–1800 mg) and MMC (4–8 mg) in the same volume of contrast medium was injected via the implanted port on Day 1, until hepatic arterial flow stagnated. One hour after this chemoembolization, continuous intra-arterial infusion of 5-FU (1250 mg), CDDP (25–50 mg) and l-LV (125 mg) for 120 h was performed using three disposable balloon infusers (Surefuser®; Nipro Co., Osaka, Japan) and three 2-valves, in principle, as outpatients. In addition, this intra-arterial infusion was repeated on Day 7. A serotonin antagonist, ramosetron hydrochloride (Nasea®; Yamanouchi Co., Tokyo, Japan), was administered intravenously or orally as antiemetic therapy. This course was repeated after the suspension of administration for 2 weeks or more. All anti-cancer therapy was discontinued when adverse effects reached level 2 of the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), Version 2.0 (31) (with the exception of platelet and leukocyte counts <50 000 and 2000/mm3, respectively, because of underlying cirrhosis). Assessment of Therapeutic Efficacy To evaluate the response to chemotherapy, serum chemistry and tumor markers, including AFP and DCP were measured at least once every month. The normal values of AFP and DCP were defined as <20 ng/ml and 40 mAU/ml, respectively. In addition, abdominal CT or dynamic MRI was also performed before and after the treatment at least once per month. The objective response and adverse events of the therapy were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) (32) and NCI-CTC, Version 2.0, respectively. Cumulative survival was estimated by the Kaplan–Meier method and the log-rank test using SPSS version 14.0J software (SPSS Japan Inc). RESULTS Clinical Effects Therapeutic response, change in tumor marker after chemotherapy and patient’s outcome are shown in Table 2. Of the 13 consecutive patients who received this therapy, complete response (CR) was observed in one patient, and partial response (PR) was observed in 12 patients. Thus, the response rate (CR or PR) was 86.7%. Two patients developed lung or lymph node metastases despite regression of liver tumors, and were regarded as having progressive disease (PD). In other words, tumor regression in the liver was observed in all patients. In four of 10 patients with PR, CT or DSA imaging demonstrated the absence of tumor after administration of anti-cancer agents for 10–13 weeks (mean 11.5 weeks). However, the tumor marker did not decrease within the normal range, and we regarded them as having PR. Serum AFP values were higher than 20 ng/ml in 11 patients before chemotherapy and decreased in all 11 patients after chemotherapy, with two patients having AFP values of <20 ng/ml. Serum DCP values were >40 ng/ml in 11 patients prior to chemotherapy and decreased in all 11 patients after chemotherapy, with seven patients having DCP values of <40 ng/ml. The 1-, 1.5-, 2- and 3-year survival rates of all 13 patients were 100, 61.5, 28.9 and 9.6%, respectively, and the median survival was 20.4 months. In six patients with PVTT, the 1-, 1.5-, 2- and 3-year survival rates were 100, 50.0, 33.3 and 0%, and the median survival was 17.1 months. Cumulative survival was not significantly different between six patients with PVTT and seven patients without PVTT (P = 0.3926). In 11 patients with therapeutic response, the 1-, 1.5-, 2- and 3-year survival rates were 100, 72.7, 34.1 and 11.4%, and the median survival was 22.1 months. Cumulative survival of 11 patients with therapeutic response significantly differed in comparison with two patients without therapeutic response (P = 0.0399). Adverse Events Adverse events are summarized in Table 3. Thrombocytopenia of greater than Grade III was observed in eight patients (61.5%), and two patients (15.4%) required platelet transfusions. Leukopenia of greater than Grade III was observed in three patients (23.1%), and two patients (15.4%) received granulocyte colony stimulating factor. Therapy was discontinued for more than 2 weeks in eight patients (61.5%) secondary to thrombocytopenia, and five of eight patients underwent laparoscopic splenectomy so that therapy could be reinitiated. At the time of embolization with DSM, most patients complained of upper abdominal pain or discomfort that was attributed to hepatic ischemia, but the pain was resolved following the intravenous administration of pentazocine hydrochloride, and disappeared spontaneously within 1 h. None of the patients experienced direct hepatotoxicity from the chemotherapy. Other adverse events included duodenal ulcer (three patients), and infection of the reservoir port (two patients). None of the patients experienced high fever or renal injury. Table 3. Adverse events with a new chemotherapeutic regimen using TACE Toxicity . Patients per grade . . Grade 0 . Grade 1 . Grade 2 . Grade 3 . Grade 4 . Thrombocytopenia 2 3 3 8 Leukopenia 6 2 2 2 3 Transient abdominal pain 4 5 4 4 Ascites 8 2 3 3 Duodenal ulcer 10 3 3 Infection of reservoir port 11 2 2 Anorexia 8 4 1 1 Nausea 8 4 1 1 Hypoalbunemia 7 6 Fever 12 1 Anemia 12 1 Diarrhea 13 Toxicity . Patients per grade . . Grade 0 . Grade 1 . Grade 2 . Grade 3 . Grade 4 . Thrombocytopenia 2 3 3 8 Leukopenia 6 2 2 2 3 Transient abdominal pain 4 5 4 4 Ascites 8 2 3 3 Duodenal ulcer 10 3 3 Infection of reservoir port 11 2 2 Anorexia 8 4 1 1 Nausea 8 4 1 1 Hypoalbunemia 7 6 Fever 12 1 Anemia 12 1 Diarrhea 13 According to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), Version 2.0. Open in new tab Table 3. Adverse events with a new chemotherapeutic regimen using TACE Toxicity . Patients per grade . . Grade 0 . Grade 1 . Grade 2 . Grade 3 . Grade 4 . Thrombocytopenia 2 3 3 8 Leukopenia 6 2 2 2 3 Transient abdominal pain 4 5 4 4 Ascites 8 2 3 3 Duodenal ulcer 10 3 3 Infection of reservoir port 11 2 2 Anorexia 8 4 1 1 Nausea 8 4 1 1 Hypoalbunemia 7 6 Fever 12 1 Anemia 12 1 Diarrhea 13 Toxicity . Patients per grade . . Grade 0 . Grade 1 . Grade 2 . Grade 3 . Grade 4 . Thrombocytopenia 2 3 3 8 Leukopenia 6 2 2 2 3 Transient abdominal pain 4 5 4 4 Ascites 8 2 3 3 Duodenal ulcer 10 3 3 Infection of reservoir port 11 2 2 Anorexia 8 4 1 1 Nausea 8 4 1 1 Hypoalbunemia 7 6 Fever 12 1 Anemia 12 1 Diarrhea 13 According to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), Version 2.0. Open in new tab Case Presentations A Patient with CR (Case 3) A 67-year-old man was diagnosed with HCC in 1989 and underwent treatment with PEI and TAE. Beginning in May 2001, the patient underwent repeat TAE for the treatment of multifocal HCC. However, the main CMN growth type tumor in subsegment 6 showed persistent growth with many small metastases in the bilateral liver lobes (Fig. 2a and b). Thus, these tumors were regarded as TAE-resistant HCC, and the patient underwent this chemotherapeutic regimen. Six months after the initiation of chemotherapy, the main tumor and intrahepatic metastases were no longer present, and plasma levels of tumor markers showed a marked decline (Fig. 2c and d). Figure 2. Open in new tabDownload slide Case 2. A 67-year-old man with contiguous multinodular growth type hepatocellular carcinoma (HCC) in subsegment 6 and multiple intrahepatic metastases of both liver lobes. Despite three trials of transcatheter arterial embolization (TAE), the main tumor showed persistent enlargement, and intrahepatic metastases increased in number (a, b). Thus, these tumors were regarded as TAE-resistant HCC, and the patient underwent this chemotherapeutic regimen. After treatment for 13 weeks, tumors were absent on computed tomography (CT) and digital subtraction angiography images (c, d). Figure 2. Open in new tabDownload slide Case 2. A 67-year-old man with contiguous multinodular growth type hepatocellular carcinoma (HCC) in subsegment 6 and multiple intrahepatic metastases of both liver lobes. Despite three trials of transcatheter arterial embolization (TAE), the main tumor showed persistent enlargement, and intrahepatic metastases increased in number (a, b). Thus, these tumors were regarded as TAE-resistant HCC, and the patient underwent this chemotherapeutic regimen. After treatment for 13 weeks, tumors were absent on computed tomography (CT) and digital subtraction angiography images (c, d). A Patient with PR, Who Underwent Laparoscopic Splenectomy Against Severe Thrombocytopenia After Treatment (Case 11) A 50-year-old man presented in October 2003 with complaints of abdominal fullness. He was diagnosed with advanced diffuse type HCC that occupied nearly the entire right lobe and part of the left lobe (Fig. 3a). Arterial portography suggested the presence of tumor thrombosis within the major trunk and the right branch of the portal vein; however, the left branch was observed via cavernous transformation (Fig. 3b). The patient was treated with this chemotherapeutic regimen; however, therapy was interrupted after 3 weeks because of a platelet count <50 000/mm3. Laparoscopic splenectomy was performed, and therapy was reinitiated 1 week later, as platelet counts had increased to >150 000/mm3. After 6 weeks of chemotherapy, tumor size had regressed markedly, portal thrombi disappeared and tumor marker levels decreased (Fig. 3c and d). The patient was considered to have PR. He died due to progression of extrahepatic metastases 13.8 months after initiation of chemotherapy, and not of liver tumor. Figure 3. Open in new tabDownload slide Case 11. A 50-year-old man had diffuse type HCC occupying more than three-quarters of the liver on CT image (a). Arterial portography suggested tumor thrombi in the major trunk and the right branch of the portal vein (arrowhead); however, the left branch was observed through cavernous transformation (b). After chemotherapy for 6 weeks, tumor had regressed markedly with small residual lesions (arrowheads) and disappearance of portal thrombi (c, d). Figure 3. Open in new tabDownload slide Case 11. A 50-year-old man had diffuse type HCC occupying more than three-quarters of the liver on CT image (a). Arterial portography suggested tumor thrombi in the major trunk and the right branch of the portal vein (arrowhead); however, the left branch was observed through cavernous transformation (b). After chemotherapy for 6 weeks, tumor had regressed markedly with small residual lesions (arrowheads) and disappearance of portal thrombi (c, d). DISCUSSION TAE is a widely used therapeutic modality for unresectable multifocal HCC and has an excellent anti-tumor effect (6). However, the survival benefits of TAE remain controversial (4) because TAE may promote deterioration of liver function in patients with cirrhosis (33), and because HCC is sometimes resistant to the TAE treatment. In histopathologic studies using resected liver, TAE induces a high degree of necrosis in encapsulated expanding growth type tumors but not in growth type tumors without capsules and in small daughter nodules or intrahepatic metastases (7–9). Hashimoto et al. (7) reported that TAE induced complete necroses in 50% of single nodular type tumors, 21% of SNE growth type tumors and 9% of other types of tumors, including massive, multiple nodular or CMN growth type. TAE resistance may be mediated by blood supply from the portal vein in the tumor boundary (7,8). Sato et al. (9) reported that survival in patients with unresectable HCC and either portal thrombosis or tumor occupying >20% of the liver does not differ between TAE and conservative treatment. Furthermore, Yamashita et al. (34) reported that the tumor type was the most important prognostic factor for determining survival after TAE. Treatment of TAE-resistant HCC is a major clinical objective, and HCC has low sensitivity to several anti-cancer agents (10–14). Several interventions were used in the present study to enhance the anti-cancer effect of 5-FU for HCC treatment. First, an implanted reservoir system was used for arterial infusion. Use of this system allows for relatively easy replenishment of administering agents into the hepatic artery (17–22) and achieves higher intrahepatic concentrations while reducing toxicity to other organ systems (35). Because 5-FU is a time-dependent agent and exerts a stronger cytocidal effect with longer exposure to cells (36), the drug was administered in the present study by means of continuous 120-h arterial infusion. Second, low-dose CDDP and l-LV were also administrated for biochemical modulation of 5-FU (37–39). 5-FU inhibits DNA synthesis by inactivation of thymidylate synthase (TS), which is caused by the formation of a complex of 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and methylene tetrahydrofolate (CH2FH4) (39). CDDP can increase the intracellular pool of CH2FH4 and tetrahydrofolate (39), whereas LV is a source of these increased intracellular folates (38). Both CDDP and LV can amplify complex formation of TS, FdUMP and folates. Ando et al. (17) reported that chemotherapeutic regimens using 5-FU and low dose CDDP (low dose FP) showed an objective response in 44.4% of HCC with portal tumor thrombosis of the main trunk. Furthermore, Yamasaki et al. (21) reported significantly better response and survival rates with low dose FP plus LV than with the same regimen without LV. In the present study, chemotherapy was combined with arterial chemoembolization using DSM and MMC. DSM, a microembolization material 45 ± 7 × 10−6 m in diameter made from potato starch, induces transient occlusion of small arteries (25,26). Since DSM is degraded by serum amylase, the duration of occlusion in the hepatic arteries by DSM is limited to 80 min (40). Thus, embolization with DSM seldom injures the drug delivery route, including the hepatic artery. Furthermore, recruitment of parasitic arteries, such as the phrenic or the omental arteries, is lower with DSM embolization compared with conventional TAE with gelatin sponge particles and iodized oil. In addition, co-administration of an anti-cancer drug with DSM reduces drug dilution by the hepatic arterial flow and enhances drug retention in tumors at a higher concentration and for a longer time than a single bolus injection (25,40). Furuse et al. (41) reported that embolization with DSM alone produced a necrotic area of 50% in 35.3% of patients with HCC. In the present study, the hepatic artery was embolized with DSM until blood flow stagnated, which should have produced anti-tumor effects from embolization alone, and increased the concentration of MMC within the liver tumors. Surprisingly, our chemotherapy showed a high rate of objective response (84.7%, 100% only as for liver lesion). All patients, including six cases with PVTT, survived for over 1 year. The prognosis of HCC invading the portal vein is extremely poor, and survival time is generally limited to several months after diagnosis (6). Thus, our regimen appears to have had a powerful anti-cancer effect and produced a significant improvement in survival. However, the number of patients in this study was relatively small, and further study with more number of patients is needed to confirm the efficacy and safety of this therapy. The chemotherapy described in the present study has several limitations. First, there was a high incidence of thrombocytopenia. In most of the patients with HCC, platelet count is relatively low due to underlying cirrhosis. Therefore, severe thrombocytopenia tends to occur easily as a result of receiving chemotherapy. We experienced marked tumor progression in some patients, who needed long interruption of treatment from thrombocytopenia. Therefore, we performed laparoscopic splenectomy when the pre-chemotherapy platelet count was <70 000/mm3, or when an interruption in chemotherapy for more than 2 weeks was required due to the thrombocytopenia that developed after treatment. In most cases, therapy could be reinitiated ∼1 week after splenectomy. Second, problems may occur with the use of the implanted reservoir system. For example, three patients developed duodenal ulcers due to recanalization of gastroduodenal arteries. Therefore, we advocate establishing complete obstruction of the right gastric or the duodenal arteries to prevent gastroduodenal injury. Third, the chemotherapy regimen is relatively complicated; treatment requires three arterial drug infusions in addition to chemoembolization with DSM using fluoroscopic imaging. We used three disposable balloon infusers and three two-valves for completing continuous arterial infusion of three drugs. This method could enable patients to receive this treatment only once per week as outpatients. With the present regimen, transaminases did not increase and liver failure did not occur, and functional status (in terms of activities of daily living) of all patients remained relatively good. In fact, functional status was higher for patients treated with the present regimen compared with patients treated with TAE treatments alone. Furthermore, this regimen did not induce post-embolization syndrome, including high fever and liver failure (34,41). In conclusion, this novel chemotherapy regimen produced good responses in patients with unresectable multifocal HCC resistant to TAE. Conflict of interest statement None declared. References 1 Ebara M , Ohto M , Sugiura N , Kita K , Yoshikawa M , Okuda K , et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients , J Gastroenterol Hepatol , 1990 , vol. 5 (pg. 616 - 26 ) Google Scholar Crossref Search ADS PubMed WorldCat 2 Seki T , Wakabayashi M , Nakagawa T , Itho T , Shiro T , Kunieda K , et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma , Cancer , 1994 , vol. 74 (pg. 817 - 25 ) Google Scholar Crossref Search ADS PubMed WorldCat 3 Rossi S , Di Stasi M , Buscarini E , Quaretti P , Garbagnati F , Squassante L , et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer , AJR Am J Roentgenol , 1996 , vol. 167 (pg. 759 - 68 ) Google Scholar Crossref Search ADS PubMed WorldCat 4 Llovet JM , Burroughs A , Bruix J . Hepatocellular carcinoma , Lancet , 2003 , vol. 362 (pg. 1907 - 17 ) Google Scholar Crossref Search ADS PubMed WorldCat 5 Ikeda K , Saitoh S , Tsubota A , Arase Y , Chayama K , Kumada H , et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma , Cancer , 1993 , vol. 71 (pg. 19 - 25 ) Google Scholar Crossref Search ADS PubMed WorldCat 6 Yamada R , Sato M , Kawabata M , Nakatsuka H , Nakamura K , Takashima S , et al. Hepatic artery embolization in 120 patients with unresectable hepatoma , Radiology , 1983 , vol. 148 (pg. 397 - 401 ) Google Scholar Crossref Search ADS PubMed WorldCat 7 Hashimoto T , Nakamura H , Hori S , Tomoda K , Nakanishi K , Murakami T , et al. Hepatocellular carcinoma: efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy , Cardiovasc Intervent Radiol , 1995 , vol. 18 (pg. 82 - 6 ) Google Scholar Crossref Search ADS PubMed WorldCat 8 Wakasa K , Sakurai M , Kuroda C , Marukawa T , Monden M , Okamura J , et al. Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma , Cancer , 1990 , vol. 65 (pg. 913 - 9 ) Google Scholar Crossref Search ADS PubMed WorldCat 9 Sato Y , Fujiwara K , Ogata I , Ohta Y , Hayashi S , Oka Y , et al. Transcatheter arterial embolization for hepatocellular carcinoma. Benefits and limitations for unresectable cases with liver cirrhosis evaluated by comparison with other conservative treatments , Cancer , 1985 , vol. 55 (pg. 2822 - 5 ) Google Scholar Crossref Search ADS PubMed WorldCat 10 Patt YZ , Claghorn L , Charnsangavej C , Soski M , Cleary K , Mavligit GM . Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver , Cancer , 1988 , vol. 61 (pg. 1884 - 8 ) Google Scholar Crossref Search ADS PubMed WorldCat 11 Lai EC , Choi TK , Cheng CH , Mok FP , Fan ST , Tan ES . Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil , Cancer , 1990 , vol. 66 (pg. 1685 - 7 ) Google Scholar Crossref Search ADS PubMed WorldCat 12 Falkson G , MacIntyre JM , Moertel CG , Johnson LA , Scherman RC . Primary liver cancer. An Eastern Cooperative Oncology Group Trial , Cancer , 1984 , vol. 54 (pg. 970 - 7 ) Google Scholar Crossref Search ADS PubMed WorldCat 13 Melia WM , Johnson PJ , Williams R . Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma , Cancer Treat Rep , 1987 , vol. 71 (pg. 1213 - 6 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 14 O’Connell MJ , Hahn RG , Rubin J , Moertel CG . Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine , Cancer , 1988 , vol. 62 (pg. 1041 - 3 ) Google Scholar Crossref Search ADS PubMed WorldCat 15 Okuda K , Ohtsuki T , Obata H , Tomimatsu M , Okazaki N , Hasegawa H , et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients , Cancer , 1985 , vol. 56 (pg. 918 - 28 ) Google Scholar Crossref Search ADS PubMed WorldCat 16 Stuart KE , Anand AJ , Jenkins RL . Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival , Cancer , 1996 , vol. 77 (pg. 2217 - 22 ) Google Scholar Crossref Search ADS PubMed WorldCat 17 Ando E , Yamashita F , Tanaka M , Tanikawa K . A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein , Cancer , 1997 , vol. 79 (pg. 1890 - 6 ) Google Scholar Crossref Search ADS PubMed WorldCat 18 Okuda K , Tanaka M , Shibata J , Ando E , Ogata T , Kinoshita H , et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment , Oncol Rep , 1999 , vol. 6 (pg. 587 - 91 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 19 Toyoda H , Nakano S , Kumada T , Takeda I , Sugiyama K , Osada T , et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma , Oncology , 1995 , vol. 52 (pg. 295 - 9 ) Google Scholar Crossref Search ADS PubMed WorldCat 20 Urabe T , Kaneko S , Matsushita E , Unoura M , Kobayashi K . Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma , Oncology , 1998 , vol. 55 (pg. 39 - 47 ) Google Scholar Crossref Search ADS PubMed WorldCat 21 Yamasaki T , Kurokawa F , Shirahashi H , Kusano N , Hironaka K , Masuhara M , et al. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma , Hepatol Res , 2002 , vol. 23 (pg. 7 - 17 ) Google Scholar Crossref Search ADS PubMed WorldCat 22 Sakon M , Nagano H , Dono K , Nakamori S , Umeshita K , Yamada A , et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches , Cancer , 2002 , vol. 94 (pg. 435 - 42 ) Google Scholar Crossref Search ADS PubMed WorldCat 23 Sugiura K . Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors , Cancer Res , 1959 , vol. 19 (pg. 438 - 45 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 24 Lindell B , Aronsen KF , Rothman U . Repeated arterial embolization of rat livers by degradable microspheres , Eur Surg Res , 1977 , vol. 9 (pg. 347 - 56 ) Google Scholar Crossref Search ADS PubMed WorldCat 25 Sigurdson ER , Ridge JA , Daly JM . Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake , Arch Surg , 1986 , vol. 121 (pg. 1277 - 81 ) Google Scholar Crossref Search ADS PubMed WorldCat 26 Dakhil S , Ensminger W , Cho K , Niederhuber J , Doan K , Wheeler R . Improved regional selectivity of hepatic arterial BCNU with degradable microspheres , Cancer , 1982 , vol. 50 (pg. 631 - 5 ) Google Scholar Crossref Search ADS PubMed WorldCat 27 Ensminger WD , Gyves JW , Stetson P , Walker-Andrews S . Phase I study of hepatic arterial degradable starch microspheres and mitomycin , Cancer Res , 1985 , vol. 45 (pg. 4464 - 7 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 28 Wollner IS , Walker-Andrews SC , Smith JE , Ensminger WD . Phase II study of hepatic arterial degradable starch microspheres and mitomycin , Cancer Drug Deliv , 1986 , vol. 4 (pg. 279 - 84 ) Google Scholar Crossref Search ADS WorldCat 29 Oken MM , Creech RH , Tormey DC , Horton J , Davis TE , McFadden ET , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , Am J Clin Oncol , 1982 , vol. 5 (pg. 649 - 55 ) Google Scholar Crossref Search ADS PubMed WorldCat 30 Stoesslein F , Ditscherlein G , Romaniuk PA . Experimental studies on new liquid embolization mixtures (Histoacryl-Lipiodol, Histoacryl-Pantopaque) , Cardiovasc Intervent Radiol , 1982 , vol. 5 (pg. 264 - 7 ) Google Scholar Crossref Search ADS PubMed WorldCat 31 National Cancer Institute-Common Toxcity Criteria (NCI-CTC) Version 2.0. April 30 1999 32 Therasse P , Arbuck SG , Eisenhauer EA , Wanders J , Kaplan RS , Rubinstein L , et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST) , J Natl Cancer Inst , 2000 , vol. 92 (pg. 205 - 16 ) Google Scholar Crossref Search ADS PubMed WorldCat 33 Pelletier G , Ducreux M , Gay F , Luboinski M , Hagège H , Dao T , et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC , J Hepatol , 1998 , vol. 29 (pg. 129 - 34 ) Google Scholar Crossref Search ADS PubMed WorldCat 34 Yamashita Y , Takahashi M , Koga Y , Saito R , Nanakawa S , Hatanaka Y , et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion , Cancer , 1991 , vol. 67 (pg. 385 - 91 ) Google Scholar Crossref Search ADS PubMed WorldCat 35 Kuan HY , Smith DE , Ensmiger WD , Knol JA , DeRemer SJ , Yang Z , et al. Regional pharmacokinetics of 5-bromo-2′-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions , Cancer Res , 1996 , vol. 56 (pg. 4724 - 7 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 36 Calabro-Jones PM , Byfield JE , Ward JF , Sharp TR . Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro , Cancer Res , 1982 , vol. 42 (pg. 4413 - 20 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 37 Scanlon KJ , Newman EM , Lu Y , Priest DG . Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells , Proc Natl Acad Sci USA , 1986 , vol. 83 (pg. 8923 - 5 ) Google Scholar Crossref Search ADS PubMed WorldCat 38 Buroker TR , O’Connell MJ , Wieand HS , Krook JE , Gerstner JB , Mailliard JA , et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer , J Clin Oncol , 1994 , vol. 12 (pg. 14 - 20 ) Google Scholar PubMed OpenURL Placeholder Text WorldCat 39 LoRusso P , Pazdur R , Redman BG , Kinzie J , Vaitkevicius V . Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma , Am J Clin Oncol , 1989 , vol. 12 (pg. 486 - 90 ) Google Scholar Crossref Search ADS PubMed WorldCat 40 Aronsen KF , Hellekant C , Holmberg J , Rothman U , Teder H . Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs , Eur Surg Res , 1979 , vol. 11 (pg. 99 - 106 ) Google Scholar Crossref Search ADS PubMed WorldCat 41 Furuse J , Ishii H , Satake M , Onaya H , Nose H , Mikami S , et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma , Am J Clin Oncol , 2003 , vol. 26 (pg. 159 - 64 ) Google Scholar Crossref Search ADS PubMed WorldCat © The Author (2008). Published by Oxford University Press. All rights reserved © The Author (2008). Published by Oxford University Press. All rights reserved
TI - Treatment of Hepatocellular Carcinoma Using Arterial Chemoembolization with Degradable Starch Microspheres and Continuous Arterial Infusion of 5-Fluorouracil
JO - Japanese Journal of Clinical Oncology
DO - 10.1093/jjco/hyn076
DA - 2008-09-01
UR - https://www.deepdyve.com/lp/oxford-university-press/treatment-of-hepatocellular-carcinoma-using-arterial-chemoembolization-m0zMybHGux
SP - 596
EP - 603
VL - 38
IS - 9
DP - DeepDyve
ER -